Louis Koman to Neuromuscular Agents
This is a "connection" page, showing publications Louis Koman has written about Neuromuscular Agents.
Connection Strength
1.827
-
Stone AV, Ma J, Callahan MF, Smith BP, Garrett JP, Smith TL, Koman LA. Dose- and volume dependent-response to intramuscular injection of botulinum neurotoxin-A optimizes muscle force decrement in mice. J Orthop Res. 2011 Nov; 29(11):1764-70.
Score: 0.373
-
Ma J, Shen J, Smith BP, Ritting A, Smith TL, Koman LA. Bioprotection of tendon repair: adjunctive use of botulinum toxin A in Achilles tendon repair in the rat. J Bone Joint Surg Am. 2007 Oct; 89(10):2241-9.
Score: 0.292
-
Balkrishnan R, Manuel JC, Smith BP, Camacho FT, Koman LA. Longitudinal examination of health outcomes associated with botulinum toxin use in children with cerebral palsy. J Surg Orthop Adv. 2004; 13(2):76-80.
Score: 0.225
-
Koman LA, Paterson Smith B, Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr Drugs. 2003; 5(1):11-23.
Score: 0.210
-
Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, Root L, Ferrari E, Garcia de Yebenes Prous J, Smith BP, Turkel C, Walcott JM, Molloy PT. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics. 2001 Nov; 108(5):1062-71.
Score: 0.194
-
Koman LA, Mooney JF, Smith BP, Walker F, Leon JM. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop. 2000 Jan-Feb; 20(1):108-15.
Score: 0.171
-
Mannava S, Mannava KA, Nazir OF, Plate JF, Smith BP, Koman LA, Tuohy CJ. Treatment of palmar hyperhidrosis with botulinum neurotoxin a. J Hand Surg Am. 2013 Feb; 38(2):398-400.
Score: 0.105
-
Stone AV, Koman LA, Callahan MF, Eckman DM, Smith BP, Plate JF, Smith TL. The effect of botulinum neurotoxin-A on blood flow in rats: a potential mechanism for treatment of Raynaud phenomenon. J Hand Surg Am. 2012 Apr; 37(4):795-802.
Score: 0.099
-
Mannava S, Plate JF, Stone AV, Smith TL, Smith BP, Koman LA, Tuohy CJ. Recent advances for the management of Raynaud phenomenon using botulinum neurotoxin A. J Hand Surg Am. 2011 Oct; 36(10):1708-10.
Score: 0.096
-
Shen J, Ma J, Elsaidi GA, Lee CA, Smith TL, Tan KH, Koman LA, Smith BP. Gene expression of myogenic regulatory factors following intramuscular injection of botulinum A toxin in juvenile rats. Neurosci Lett. 2005 Jun 24; 381(3):207-10.
Score: 0.062